These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 23825028)

  • 41. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
    Yang S; Zhang Y; Meng F; Liu Y; Xia B; Xiao M; Xu Y; Ning X; Li H; Lou G
    Biomarkers; 2013 May; 18(3):257-63. PubMed ID: 23566000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers.
    Sun Q; Zhao H; Zhang C; Hu T; Wu J; Lin X; Luo D; Wang C; Meng L; Xi L; Li K; Hu J; Ma D; Zhu T
    Oncotarget; 2017 Jun; 8(26):42983-42996. PubMed ID: 28562334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
    Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
    Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    Gan A; Green AR; Nolan CC; Martin S; Deen S
    Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.
    Yang D; Sun Y; Hu L; Zheng H; Ji P; Pecot CV; Zhao Y; Reynolds S; Cheng H; Rupaimoole R; Cogdell D; Nykter M; Broaddus R; Rodriguez-Aguayo C; Lopez-Berestein G; Liu J; Shmulevich I; Sood AK; Chen K; Zhang W
    Cancer Cell; 2013 Feb; 23(2):186-99. PubMed ID: 23410973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.
    Liu Z; Liu J; Segura MF; Shao C; Lee P; Gong Y; Hernando E; Wei JJ
    J Pathol; 2012 Oct; 228(2):204-15. PubMed ID: 22322863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
    Berkel C; Cacan E
    Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Grading ovarian serous carcinoma using a two-tier system.
    Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG
    Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.
    Suryawanshi S; Vlad AM; Lin HM; Mantia-Smaldone G; Laskey R; Lee M; Lin Y; Donnellan N; Klein-Patel M; Lee T; Mansuria S; Elishaev E; Budiu R; Edwards RP; Huang X
    Clin Cancer Res; 2013 Mar; 19(5):1213-24. PubMed ID: 23362326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
    Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
    Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
    Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
    J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.
    Peng J; Mo R; Ma J; Fan J
    World J Surg Oncol; 2015 May; 13():175. PubMed ID: 25951903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Construction and Investigation of an LINC00284-Associated Regulatory Network in Serous Ovarian Carcinoma.
    Wang S; Zhang L; Tao L; Pang L; Fu R; Fu Y; Liang W; Ding Y; Jia W
    Dis Markers; 2020; 2020():9696285. PubMed ID: 32076467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
    Bodurka DC; Deavers MT; Tian C; Sun CC; Malpica A; Coleman RL; Lu KH; Sood AK; Birrer MJ; Ozols R; Baergen R; Emerson RE; Steinhoff M; Behmaram B; Rasty G; Gershenson DM
    Cancer; 2012 Jun; 118(12):3087-94. PubMed ID: 22072418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
    Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
    Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas].
    Shen Y; Yang F; Liu JS
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636
    [No Abstract]   [Full Text] [Related]  

  • 60. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.
    Abdallah R; Chon HS; Bou Zgheib N; Marchion DC; Wenham RM; Lancaster JM; Gonzalez-Bosquet J
    Int J Gynecol Cancer; 2015 Jul; 25(6):1000-9. PubMed ID: 26098088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.